These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 29468559)

  • 21. Intensifying insulin regimen after basal insulin optimization in adults with type 2 diabetes: a 24-week, randomized, open-label trial comparing insulin glargine plus insulin glulisine with biphasic insulin aspart (LanScape).
    Vora J; Cohen N; Evans M; Hockey A; Speight J; Whately-Smith C
    Diabetes Obes Metab; 2015 Dec; 17(12):1133-41. PubMed ID: 26085028
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Insulin therapy in type 2 diabetes patients failing oral agents: cost-effectiveness of biphasic insulin aspart 70/30 vs. insulin glargine in the US.
    Ray JA; Valentine WJ; Roze S; Nicklasson L; Cobden D; Raskin P; Garber A; Palmer AJ
    Diabetes Obes Metab; 2007 Jan; 9(1):103-13. PubMed ID: 17199725
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Similar glucose control with basal-bolus regimen of insulin detemir plus insulin aspart and thrice-daily biphasic insulin aspart 30 in insulin-naive patients with type 2 diabetes: Results of a 50-week randomized clinical trial of stepwise insulin intensification.
    Malek R; Ajili F; Assaad-Khalil SH; Shinde A; Chen JW; Van den Berg E
    Diabetes Metab; 2015 Jun; 41(3):223-30. PubMed ID: 25483023
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical experience with BIAsp 30: results from the Indonesian cohort of the international A₁chieve study.
    Soewondo P; Pramono RB; Langi YA; Soetedjo NN; Kshanti IA
    Diabetes Res Clin Pract; 2013 Apr; 100 Suppl 1():S54-9. PubMed ID: 23647720
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of insulin degludec/insulin aspart versus biphasic insulin aspart 30 in Chinese adults with type 2 diabetes: A phase III, open-label, 2:1 randomized, treat-to-target trial.
    Yang W; Ma J; Hong T; Liu M; Miao H; Peng Y; Wang C; Xu X; Yang T; Nielsen AM; Pan L; Liu W; Zhao W
    Diabetes Obes Metab; 2019 Jul; 21(7):1652-1660. PubMed ID: 30869183
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An analysis of the short- and long-term cost-effectiveness of starting biphasic insulin aspart 30 in insulin-naïve people with poorly controlled type 2 diabetes.
    Shafie AA; Gupta V; Baabbad R; Hammerby E; Home P
    Diabetes Res Clin Pract; 2014 Nov; 106(2):319-27. PubMed ID: 25305133
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety and efficacy of biphasic insulin aspart 30 in type 2 diabetes patients switched from either biphasic or basal human insulin: results from the Gulf cohort of the A1 chieve study.
    Almansari A; Khader S; Kharawagh A; AbdelFattah W; Badawy T
    Int J Clin Pract; 2014 Jul; 68(7):850-6. PubMed ID: 24548757
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical effectiveness of biphasic insulin aspart 30:70 versus biphasic human insulin 30 in UK general clinical practice: a retrospective database study.
    Morgan CL; Evans M; Toft AD; Jenkins-Jones S; Poole CD; Currie CJ
    Clin Ther; 2011 Jan; 33(1):27-35. PubMed ID: 21397771
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Composite cardiovascular risk and BMI affected comparative profiles of BIAsp 30 + metformin vs BIAsp 30 monotherapy: a MERIT post-hoc analysis.
    Guo L; Chang B; Chen L; Yang L; Liu Y; Feng B; He Q
    Sci Rep; 2021 Feb; 11(1):4131. PubMed ID: 33602996
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Insulin degludec/insulin aspart versus biphasic insulin aspart 30 in Asian patients with type 2 diabetes inadequately controlled on basal or pre-/self-mixed insulin: a 26-week, randomised, treat-to-target trial.
    Kaneko S; Chow F; Choi DS; Taneda S; Hirao K; Park Y; Andersen TH; Gall MA; Christiansen JS;
    Diabetes Res Clin Pract; 2015 Jan; 107(1):139-47. PubMed ID: 25498130
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A comparison of twice-daily biphasic insulin aspart 70/30 and once-daily insulin glargine in persons with type 2 diabetes mellitus inadequately controlled on basal insulin and oral therapy: a randomized, open-label study.
    Ligthelm RJ; Gylvin T; DeLuzio T; Raskin P
    Endocr Pract; 2011; 17(1):41-50. PubMed ID: 20713345
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Twice-daily biphasic insulin aspart 30 versus biphasic human insulin 30: a double-blind crossover study in adults with type 2 diabetes mellitus.
    McSorley PT; Bell PM; Jacobsen LV; Kristensen A; Lindholm A
    Clin Ther; 2002 Apr; 24(4):530-9. PubMed ID: 12017398
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intensification to biphasic insulin aspart 30/70 (BIAsp 30, NovoMix 30) can improve glycaemic control in patients treated with basal insulins: a subgroup analysis of the IMPROVE observational study.
    Gumprecht J; Benroubi M; Borzi V; Kawamori R; Shaban J; Shah S; Shestakova M; Wenying Y; Ligthelm R; Valensi P;
    Int J Clin Pract; 2009 Jun; 63(6):966-72. PubMed ID: 19504715
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Attainment of glycaemic goals in type 2 diabetes with once-, twice-, or thrice-daily dosing with biphasic insulin aspart 70/30 (The 1-2-3 study).
    Garber AJ; Wahlen J; Wahl T; Bressler P; Braceras R; Allen E; Jain R
    Diabetes Obes Metab; 2006 Jan; 8(1):58-66. PubMed ID: 16367883
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Improved postprandial glycemic control with biphasic insulin aspart relative to biphasic insulin lispro and biphasic human insulin in patients with type 2 diabetes.
    Hermansen K; Colombo M; Storgaard H; ØStergaard A; Kølendorf K; Madsbad S
    Diabetes Care; 2002 May; 25(5):883-8. PubMed ID: 11978685
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost-effectiveness of biphasic insulin aspart versus insulin glargine in patients with type 2 diabetes in China.
    Palmer JL; Beaudet A; White J; Plun-Favreau J; Smith-Palmer J
    Adv Ther; 2010 Nov; 27(11):814-27. PubMed ID: 21061114
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of biphasic insulin aspart 30 given three times daily or twice daily in combination with metformin versus oral antidiabetic drugs alone in patients with poorly controlled type 2 diabetes: a 16-week, randomized, open-label, parallel-group trial conducted in russia.
    Ushakova O; Sokolovskaya V; Morozova A; Valeeva F; Zanozina O; Sazonova O; Zhadanova E; Starceva M; Kazakova E; Saifullina M; Shapiro I; Tarasov A; Al-Tayar B; Starkova N
    Clin Ther; 2007 Nov; 29(11):2374-84. PubMed ID: 18158078
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of exenatide with biphasic insulin aspart 30 on glucose variability in type 2 diabetes: study protocol for a randomized controlled trial.
    Xu S; Liu X; Ming J; Ji Q
    Trials; 2016 Mar; 17():160. PubMed ID: 27009108
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of a soluble co-formulation of insulin degludec/insulin aspart vs biphasic insulin aspart 30 in type 2 diabetes: a randomised trial.
    Niskanen L; Leiter LA; Franek E; Weng J; Damci T; Muñoz-Torres M; Donnet JP; Endahl L; Skjøth TV; Vaag A
    Eur J Endocrinol; 2012 Aug; 167(2):287-94. PubMed ID: 22660026
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and safety of three-times-daily versus twice-daily biphasic insulin aspart 30 in patients with type 2 diabetes mellitus inadequately controlled with basal insulin combined with oral antidiabetic drugs.
    Yang W; Ersoy C; Wang G; Ye S; Liu J; Miao H; Asirvatham A; Werther S; Kadu P; Chow F
    Diabetes Res Clin Pract; 2019 Apr; 150():158-166. PubMed ID: 30872064
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.